Pluribioactive Antifungal Drug Controlled Release Systems

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current antifungal drugs are primarily used for treating fungal infections and lack exploration for additional bioactivities such as antineoplastic, antibacterial, antirestenotic, and spermiostatic effects, despite their potential pluribioactive properties.

Innovation Solution

Development of controlled release systems for pluribioactive antifungal drugs like miconazole and ketoconazole, incorporating them into absorbable or non-absorbable polymeric systems for applications beyond fungal infections, including cancer treatment, vascular restenosis prevention, and contraception.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If antifungal drugs are used solely for treating fungal infections, then their antifungal efficacy is optimized, but their potential additional bioactivities (antineoplastic, antibacterial, antirestenotic, spermiostatic) remain unexploited

Engineering Contradiction:
Improvepluribioactive potentialVSAvoiddrug application system
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent applies multi-functionality by formulating antifungal drugs (miconazole, ketoconazole, itraconazole, voriconazole, amphotericin B) in controlled release systems that enable them to perform multiple bioactivities simultaneously - antifungal, antineoplastic, antibacterial, antirestenotic, and spermiostatic effects - thereby resolving the contradiction between versatility and system complexity

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent utilizes parameter changes by modifying the release characteristics and concentration profiles of antifungal drugs through controlled release formulations, allowing the same drug to exhibit different bioactivities at different concentrations and time points, thus enabling pluribioactive potential without requiring multiple separate drugs

Inventive Principle:
Principle #35Parameter changes

2Duration of action of moving object

If azole-type antifungal drugs are used in controlled delivery systems, then their bioavailability and sustained release are improved, but their water insolubility creates formulation challenges

Engineering Contradiction:
Improvesustained release durationVSAvoidformulation compatibility
Core Design Contradiction:
Duration of action of moving objectVSEase of manufacture

Solution Approach 1:

The patent employs intermediaries in the form of controlled release matrices and carriers that facilitate the incorporation and sustained release of water-insoluble azole-type antifungal drugs, enabling prolonged duration of action while overcoming formulation challenges through appropriate matrix selection and drug formulation techniques

Inventive Principle:
Principle #24Intermediary (Mediator)

3Adaptability or versatility

If multiple bioactivities are pursued with a single drug, then therapeutic versatility is enhanced, but the complexity of developing and regulating multiple indications increases

Engineering Contradiction:
Improvenumber of bioactivitiesVSAvoidclinical evidence reliability
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies preliminary action by conducting in vitro and in vivo studies to preliminarily establish the pluribioactive potential of antifungal drugs before clinical application, demonstrating antifungal, antineoplastic, antibacterial, antirestenotic, and spermiostatic activities through controlled release systems, which builds the foundation for reliable multi-indication use

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The controlled release systems effectively manifest additional bioactivities, demonstrating significant inhibition of cancer cells, bacterial and fungal growth, and sustained drug release profiles, showcasing the pluribioactive potential of miconazole and ketoconazole.

Implementation Method 1

controlled release systems for pluribioactive antifungal drugs

Methodology Applied
Scientific EffectDiffusion: Diffusion

Implementation Method 2

absorbable or non-absorbable polymeric systems

Methodology Applied
Scientific EffectPolymer degradation: Decomposition (biological)

Data Source

PatentUS9006278B2Controlled release systems of pluribioactive antifungal drugs and applications thereof
Publication Date: 2015.04.14 POLY MED INC

AI summary

Controlled release systems release at least one pluribioactive antifungal drug exhibiting at least one additional bioactivity from the group consisting of spermiostatic, antineoplastic, antibacterial, antirestenotic and antiviral activities. The drug release system is designed for use as a spermiostatic contraceptive, intravaginal ringed-mesh which may also exhibit antiviral activity, an in situ-forming implant for treating different forms of cancer and topical film for treating or preventing bacterial and fungal infections.